Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof
Provided herein are various salts, including tris(hydroxymethyl)aminomethane salts and sodium salts, as well as various crystalline forms of the compound represented by the structural formula: Also provided are pharmaceutical compositions comprising these salts and crystalline forms, methods for their manufacture, and uses thereof for treating conditions, including but not limited to conditions that would benefit from inhibition of dihydroorotate dehydrogenase (DHODH).
1. A tris(hydroxymethyl)aminomethane salt of a compound represented by the formula of Compound 1:
2. The tris(hydroxymethyl)aminomethane salt of claim 1 , wherein the salt is anhydrate.
3. The tris(hydroxymethyl)aminomethane salt of claim 1 , wherein the salt is crystalline Form A characterized by X-ray powder diffraction peaks at 2θ angles (±0.2°) 4.4°, 15.6°, and 18.9°.
4. The tris(hydroxymethyl)aminomethane salt of claim 3 , wherein the crystalline Form A is further characterized by X-ray powder diffraction peaks at 2θ angles (±0.2°) 11.5°, 16.4°, 19.6° and 25.5°.
5. The tris(hydroxymethyl)aminomethane salt of claim 3 , wherein the crystalline Form A is further characterized by at least one X-ray powder diffraction peaks at 2θ angles (±0.2°) selected from 8.7°, 15.2°, 18.6°, 21.4° and 25.1°.
6. The tris(hydroxymethyl)aminomethane salt of claim 3 , wherein the crystalline Form A is characterized by an X-ray powder diffraction pattern substantially similar to FIG. 7 A .
7. The tris(hydroxymethyl)aminomethane salt of claim 1 , wherein the crystalline form is crystalline Form B characterized by X-ray powder diffraction peaks at 2θ angles (±0.2°) 6.0°, 7.0°, and 7.2°.
8. The tris(hydroxymethyl)aminomethane salt of claim 7 , wherein the crystalline Form B is further characterized by at least one X-ray powder diffraction peak at 2θ angles (±0.2°) selected from 9.3° and 12.5°.
9. The tris(hydroxymethyl)aminomethane salt of claim 7 , wherein the crystalline Form B is further characterized by at least one X-ray powder diffraction peaks at 2θ angles (±0.2°) selected from 15.6° and 19.0°.
10. The tris(hydroxymethyl)aminomethane salt of claim 7 , wherein the crystalline Form B is characterized by an X-ray powder diffraction pattern substantially similar to FIG. 8 A .
11. The tris(hydroxymethyl)aminomethane salt of claim 1 , wherein the crystalline form is crystalline Form C characterized by X-ray powder diffraction peaks at 2θ angles (±0.2°) 4.5°, 13.5°, and 18.0°.
12. The tris(hydroxymethyl)aminomethane salt of claim 11 , wherein the crystalline Form C is further characterized by at least one X-ray powder diffraction peak at 2θ angles (±0.2°) selected from 14.3°, 18.3°, and 23.5°.
13. The tris(hydroxymethyl)aminomethane salt of claim 11 , wherein the crystalline Form C is further characterized by at least one X-ray powder diffraction peaks at 2θ angles (±0.2°) selected from 16.3°, 19.0°, 21.2°, 22.5°, and 22.8°.
14. The tris(hydroxymethyl)aminomethane salt of claim 11 , wherein the crystalline Form C is characterized by an X-ray powder diffraction pattern substantially similar to FIG. 9 A .
15. A pharmaceutical composition comprising the tris(hydroxymethyl)aminomethane salt of claim 1 and one or more pharmaceutically acceptable excipients.
16. A method of treating cancer in a subject, comprising administering to the subject an effective amount of the tris(hydroxymethyl)aminomethane salt of claim 1 .
17. The method of claim 16 , wherein the cancer is selected from
lung cancer, breast cancer, triple negative breast cancer, melanoma, glioblastoma, prostate cancer, colon cancer, pancreatic cancer, bone cancer, cancer of the head or neck, skin cancer, cutaneous or intraocular malignant endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, solid tumors of childhood, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, an environmentally induced cancer, and a PTEN mutant cancer; and biliary tract cancer or cancer of the ampulla of Vater, non-small cell lung cancer, bronchoalveolar carcinoma, liver cancer, cancer of the ovary, and cancer of the upper aerodigestive tract.
18. The method of claim 16 , wherein the cancer is a hematological cancer selected from
acute myeloid leukemia, multiple myeloma, B-prolymphocytic leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, follicular lymphoma, diffuse large B cell lymphoma, anaplastic large cell lymphoma, mantle cell lymphoma, lymphocytic lymphoma cancer of the bladder, primary CNS lymphoma, and T-cell lymphoma;
chemotherapy-resistant acute myeloid leukemia, cytarabine-resistant acute myeloid leukemia, acute monocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, diffuse mixed cell lymphoma, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasms, primary effusion lymphoma, erythroleukemia, chronic myeloid leukemia, chronic monocytic leukemia, double hit diffuse large B cell lymphoma, and triple hit diffuse large B cell lymphoma;
angioimmunoblastic lymphoma, Burkitt's lymphoma, Burkitt-like lymphoma, blastic NK-cell lymphoma, cutaneous T-cell lymphoma, lymphoblastic lymphoma, MALT lymphoma, mediastinal large B-cell lymphoma, nodal marginal zone B-cell lymphoma, small lymphocytic lymphoma, thyroid lymphoma, follicular lymphoma, Waldenstrom's macroglobulinemia, essential thrombocythemia, chronic idiopathic myelofibrosis, and polyeythemia rubra vera.
19. A method of treating cancer in a subject wherein the cancer is responsive to inhibition of dihydroorotate dehydrogenase, comprising administering to the subject an effective amount of the tris(hydroxymethyl)aminomethane salt of claim 1 .
20. A method of treating a condition or a disease selected from a viral-mediated disease, transplant rejection, rheumatoid arthritis, psoriasis, an autoimmune disease, or an inflammatory disorder in a subject, comprising administering to the subject an effective amount of the tris(hydroxymethyl)aminomethane salt of claim 1 .
21. A method of inhibiting growth and/or metastasis of tumor cells in a subject wherein the tumor cells are responsive to inhibition of dihydroorotate dehydrogenase, comprising administering to the subject an effective amount of the tris(hydroxymethyl)aminomethane salt of claim 1 .
22. A method of inhibiting dihydroorotate dehydrogenase in a subject, comprising administering to the subject an effective amount of the tris(hydroxymethyl)aminomethane salt of claim 1 .